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Abstracts of invited paperst
Symposium on Molecular Genetics and
diagnosis of leukaemia
Developmentally regulated genes and chromosome
abnormalities in human lymphoid malignancies
T.H. Rabbitts, T. Boehm, L. Foroni, J. Greenberg & P.
Sherrington
Medical Research Council Laboratory of Molecular Biology,
Hills Road, Cambridge CB2 2QH, England.
There are a wide variety of tumour-associated chromosomal
abnormalities in B and T cell malignancies which involve, on
one chromosome, either an immunoglobulin or T cell
receptor gene and, on the other chromosome, a putative
oncogene, presumably activated by the abberration, and thus
involved in the pathogenesis of the tumour cell carrying the
abnormality. Although some of these abnormalities involve
cellular counterparts of known v-oncogenes, e.g. the c-myc
proto-oncogene at the site of chromosome translocation in
Burkitt's B-cell lymphoma, more frequently the gene or
region of DNA identified on the second involved
chromosome location is not related to any
retrovirally-encoded transduced oncogene. Why should the
majority of lymphoid-specific chromosome abnormalities not
involve oncogenes which naturally occur in transforming
retroviruses? A possible explanation is that these newly
identified loci carry differentiation stage-specific genes whose
capability for involvement in tumorigenesis is restricted to a
narrow time window of expression in ontogeny. In this
model, the propensity for creation of chromosomal
abnormalities via the rearranging genes (i.e. Ig and TCR)
would merely circumvent the developmental switching of
these genes by causing inappropriate gene expression. Such
violations in expression patterns may involve abnormalities
of lymphoid stage-specific genes or perhaps of tissue-specific
genes not normally expressed in lymphoid cells. T cell
tumour abnormalities involving chromosomes 10, 11 and 14
are discussed, with reference to these issues.
The Bcl-2 proto-oncogene in neoplasia
S.J. Korsmeyer, T.J. McDonnell, G. Nunez, U. Jaeger, D.
Hockenberry & R. Young
Howard Hughes Med. Inst., Dept Medicine, Mol. Microbiol.,
Washington Univ. School Med., St. Louis, MO 63110, USA.
Despite the mature B cell phenotype of follicular lymphoma
the t (14:18) appear to occur early in pre B cell development
*Enquiries to the BACR Secretariat, Institute of Biology, 20 Queens-
bury Place, London SW7 2DZ, UK.
tReprints of these abstracts are not available - Ed.
juxtaposing a new gene from chromosome 18, Bcl-2, with
the immunoglobulin (Ig) heavy chain gene locus at 14q32.
Normal expression of Bcl-2 is associated with the activation
of normal B cells. Bc1-2 is an enormous gene with an
approximately 350 kb intron and encodes a 25 kDa
intracellular membrane associated protein. The molecular
consequence of translocation generates a Bcl-2-Ig fusion
gene and chimeric RNAs. The Bcl-2-Ig allele is deregulated
resulting in elevated RNA and elevated 25 kDa Bcl-2
protein. Retroviral vectors introduced a deregulated Bcl-2
into B lymphoblastoid cells which improved their
clonogenicity and complemented c-myc in promoting
tumorigenesis. Moreover, deregulated Bc1-2 provided a death
sparing effect to IL-3 dependent pro B lymphocytes,
promyelocytes, and mast cells when deprived of IL-3. Bcl-2
did not influence cell cycle progression, but instead delayed
the onset of death. This effect was not limited to the IL-3
pathway; however, no effects were seen in IL-2 dependent T
cells. Transgenic mice bearing a deregulated Bcl-2-Ig
minigene produce excess 25 kDa protein and develop a
polyclonal follicular lymphoproliferation. Transgenics
selectively accumulate a 4-fold excess of small IgM/IgD B
cells that are resting in Go, but capable of normal
proliferative responses. This select population demonstrates
an extended survival. Moreover, Bcl-2-Ig transgenics show a
progression from indolent to monoclonal high grade
lymphoma providing a model to identify the two
complementing oncogenes.
Clonal analysis and the diagnosis of lymphoid malignancy
based on antigen receptor gene rearrangements
J. Sklar
Division of Diagnostic Molecular Biology, Department of
Pathology, Brigham and Women's Hospital and Harvard
Medical School, Boston, Massachusetts 02115, USA.
Clonal rearrangements of antigen genes (ARGs) provide
useful markers in the evaluation of tissue biopsy specimens
for lymphocytic malignancy. These markers are usually
analysed by Southern blot hybridisation of biopsy tissue
DNA using probes for immunoglobulin or T cell receptor
(TCR) genes. Clonal cells composing malignant processes
generally carry uniform rearrangements of these genes, which
can be detected as bands in non-germline positions within
Southern blot autoradiograms. In contrast, benign processes
contain cells with diverse re-arrangements of ARGs, none of
which is individually sufficiently abundant to be detected as a
band in the autoradiogram. In addition to providing valuable
information about the clonality (and, indirectly, about the
malignancy) of tissues, ARG rearrangements have been used
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to determine the B- or T-lineage of lymphoid tumours and to
identify multiple B- and/or T-lineage clones or subclones
within single cases of lymphoproliferative disease. However,
recent experience with diagnostic applications of ARG
rearangements has revealed a number of problems with this
type of analysis. For example, certain clinically benign
disorders appear to be clonal; some T cell lymphomas lack
detectable ARG rearrangements; the ARG rearrangement
detected may be discordant with the tumour phenotype; and
under various circumstances, rearrangements may not be
stable in subpopulations of tumour cells. Other problems
with Southern blot analysis of antigen receptor genes are
technical and include the limited sensitivity of the procedure
(about 1% tumour to normal cells), the time necessary to
obtain interpretable results, and the reliance on radioactivity
to detect rearrangements. Sensitivity is a particularly
important issue in monitoring residual disease after therapy.
For this purpose we have recently adapted the polymerase
chain reaction (PCR) technique for detecting clonally specific
DNA sequences at the junctions of rearranged segments in
gamma TCR genes of lymphoblastic leukaemias. In this way,
we have been able to detect one malignant cell out of one
million total cells. We have also used PCR to detect clonal
rearrangements of gamma TCR genes by analysing the
amplified products on gradient denaturing gels, thereby
permitting assessment of clonality within one day and
without resorting to radioactivity.
Molecular genetics of the Ph-chromosome
Multidrug resistance in leukaemia
H. Preisler, H. Sato, Y. Li & A. Raza
Barrett Centerfor Cancer Prevention Research and Treatment
234 Goodman Street, Cincinnati, Ohio 45267-0502, USA.
Multidrug resistance is a serious impediment to the delivery
of effective chemotherapy. The over-expression of a gene
located on chromosome 7, the MDR1 gene, is associated with
one form of multidrug resistance. In our studies of acute
non-lymphocytic leukaemia (ANLL), we have used Northern
blot analysis to measure MDR, transcript levels. These
studies have demonstrated that poor responsiveness to
chemotherapy is associated with over expression of the gene.
Poor responsiveness is manifested by the necessity of being
treated with more than one course of chemotherapy to enter
CR and short remissions. Overexpression of the MDR1 gene
was unassociated with gene amplification but appears to be
common in leukaemic cells which bear abnormalities of
chromosome 7. Overexpression is present in 25% of newly
diagnosed patients with standard risk leukaemia and in 50%
of patients with secondary ANLL or relapsed leukaemia. We
are currently evaluating the possible clinical utility of
antibodies to the pl70 MDR, glycoprotein both to detect
and possibly to reverse multidrug resistance. These studies
have led us to address a laboratory phenomenon which has
received little attention: the fact that the presence of multi-
drug resistance in tissue culture cell lines is at times
associated with non-equivalent resistance to the chemo-
therapeutic agents to which the cells are resistant.
Symposium on epidemiology of lymphoma and
leukaemia
L.M. Wiedemann
Leukaemia Research Fund Centre at the Institute for Cancer
Research, London SW3 6JB, UK.
The molecular analysis of the DNA, RNA and protein pro-
ducts which result from the reciprocal translocation resulting
in the Philadelphia chromosome (Ph), (t(9;22) (q34;ql 1)) has
resulted in the identification of two related but distinct forms
of chimaeric BCR/ABL protein, known as p210 and p190.
Whereas the p210 encoded form of the Ph-translocation is
associated with both acute leukaemias of various
haematopoetic lineages and chronic myelogenous leukaemia
(CML), the p190 form is associated primarily (if not exclus-
ively) with acute forms of leukaemia.
The junctions between chromosome 22 and chromosome 9
occur within the introns of the BCR and ABL genes respec-
tively such that the spliced mRNA product of a Ph
chromosome can produce only a limited number of exon/
exon junctions despite the large variation in location of the
DNA breakpoints. Analysis of RNA using the polymerase
chain reaction (PCR) has confirmed the hybrid nature of the
junctions encoding the BCR/ABL fusion proteins. This tech-
nique allows the rapid distinction between the p190 and p210
types of Ph-positive leukaemia. This is important, as it is still
unclear what relationship exists between the acute phase of
CML (or blast crisis) and de novo Ph-positive acute
leukaemia. It is possible that p210 positive cases of acute
leukaemia represent early transformation of CML without an
overt chronic phase. Unambiguous identification of the
molecular phenotypes may help to elucidate this question.
In addition, the technique is highly specific for this
leukaemia specific marker and can be used in the detection of
residual disease following bone marrow transplant or various
other treatments. We are currently assessing its potential
value in the prognosis and clinical management of Ph-
positive leukaemia.
Overview of adult lymphomas/leukaemias
R.A. Cartwright
Leukaemia Research Fund Centre for Clinical Epidemiology,
17 Springfield Mount, Leeds LS2 9NG, UK.
Adult lymphomas and leukaemias when grouped together
have a crude incidence rate of over 25/100,000 per year and
as such represent a substantial public health burden. The
specific problems associated with studies of their epidemi-
ology are discussed to enable interpretation of the available
evidence. Then recent work is presented on the descriptive
epidemiology of some of these conditions and the use of
these data in producing hypotheses for testing the aetiology
of the various conditions is critically reviewed.
The key risk factors are discussed and the deficiencies in
our present knowledge are highlighted. Finally, possible
aetiologic links between different disease groups are present-
ed and future study directions are highlighted.
Childhood leukaemia: descriptive epidemiology and post-natal
aetiological factors
M.S. Linet & S.S. Devesa
Analytic Studies Section, Biostatistics Branch, Epidemiology
and Biostatistics Program, National Cancer Institute,
Bethesda, MD 20892, USA.
Recently international interest in the aetiology of childhood
leukaemia has increased as four large case-control studies
and several smaller effects are about to commence. The
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leads identified in epidemiological studies during the past
10-15 years and several exciting new theories about the
origins of this heterogeneous haematological malignancy.
Although there is less international variation for childhood
leukaemia incidence than for many adult malignancies, rates
appear to vary 4-5-fold and are lowest among African
blacks and among US blacks, Kuwaitis, non-Jews in Israel
and Bombay Indians. Intermediate rates have been reported
for Asian populations, among whom incidence of acute non-
lymphocytic leukaemia (ANLL) varies substantially. The
proportion of other and unspecified rates also varies
markedly, possibly hampering comparisons of the specific cell
types. Incidence of acute lymphocytic leukaemia (ALL)
among Filipinos, Chinese and Japanese in the USA was
higher than among Asians from other countries. Highest
ALL rates were observed in Costa Rica, Los Angeles His-
panics and New South Wales, Australia, with somewhat
lower rates among Caucasians in Europe and North
America. Although childhood leukaemia incidence has not
changed greatly in the USA, mortality has decreased since
the mid 1960s due to improved therapy resulting in pro-
longed survival. Age-specific variation in rates by cell type,
the ALL/ANLL and lymphoma/leukaemia ratios will be
examined in the context of new aetiologic hypotheses about
primarily postnatal, and to a lesser extent prenatal, infections
and immunological function, familial and genetic factors,
medications, parental occupations, and electromagnetic field
exposures.
Clusters of leukaemia: analysis and consequences of new tech-
niques
F.E. Alexander
Leukaemia Research Fund Centre for Clinical Epidimiology,
Leeds, UK.
Investigations of leukaemia clustering have normally pro-
ceeded in two directions. They have followed reports of
individual excesses or concentrated their attention on one
particular site or category of site. These event and site driven
analyses are of course essential but there is a third approach.
This involves the study of a large body of incidence data and
asking of it fairly general questions. First and crucially: is a
tendency to cluster a feature of the normal pattern? New
statistical methods of analysis have been applied to data
from the Leukamia Research Fund Data Collection Survey
and suggest that clustering is not common.
Secondly a pattern which is found can be studied for
aetiological clues. These can be generated entirely by the data
suggesting that certain sub-types or age-groups show a par-
ticular tendency to aggregate. Alternatively they can relate
incidence patterns to external natural geographical features
or industrial sites. The direction in which subsequent research
can proceed are illustrated using AML and related condi-
tions.
Current attitudes to radiation and leukaemia
R.H. Mole
Bayworth Lane, Boar's Hill, Oxford OXI SDF, UK.
Therapy in childhood using radium-224, an a-emitting Ra
isotope, caused many osteosarcomas but no leukaemia. Since
no osteosarcoma has been noted in a child or adult at
Sellafield or Dounreay, it is unlikely that leukaemia at either
site was caused by an osteotropic a-emitting radionuclide.
Recent revision of bomb dosimetry leaves unexplained the
marked difference in induced CML between Hiroshima and
Nagasaki. Induction of AML in bomb survivors depended
markedly on exposure age, children being least sensitive.
In 80,000 irradiated cases of cervix Ca induced malignant
disease was less than predicted from the bomb survivor
experience. The dose-response for induced leukaemia was
highly curvilinear as predicted by radiobiological considera-
tions. In subjects with Ca ovary or Hodgkin's disease
chemotherapy seemed much more leukaemogenic than
radiotherapy.
Re-analysis of OCCS data shows a sharply reduced induc-
tion of childhood cancer following diagnostic radiography, beginning in those born in 1958. In those born 12 or more
years later it may be increasing again.
Overview of retrovirus
D. Onions
Leukaemia Research Fund Virus Centre, Department of Veterinary Pathology, University of Glasgow Veterinary
School, Glasgow G61 IQH, UK.
The retroviruses are characterised by a life cycle in which the
RNA genome of the virion is transcribed into a double-
stranded DNA provirus which becomes integrated into
chromosomal DNA.
The leukaemogenic retroviruses can be divided into two
broad groups. One group exemplified by the feline, murine
and the avian viruses is associated with a wide range of
oncogenic and non-oncogenic conditions. These viruses rep- licate efficiently in their hosts and leukaemogenesis is
associated with direct interaction of the virus with cellular
oncogenes, either by insertional mutagenesis or by transduc-
tion. The recent finding of functional T-cell antigen receptor beta-chain within a feline provirus suggests that this structure
may be added to the list of retrovirus-associated oncogenes. The other major group of leukaemogenic retroviruses
includes the human retroviruses HTLV-1 and HTLV-2.
These viruses establish a latent infection within most infected
cells of their host and transmission probably requires the
transfer of whole blood. In addition to the major structural
genes these viruses encode a tax protein which indirectly transactivates both the provirus and the cellular genes includ-
ing the IL-2 and IL-2 receptor genes. The importance of
transactivation of cellular genes in leukaemogenesis is cur-
rently an area of major interest in retrovirology.
Epidemiology of HTLV-I in the Caribbean and Japan
A. Manns & W.A. Blattner
Viral Epidemiology Section, NIH, Bethesda, MD, USA.
The HTLV-I virus is associated with the adult T-cell
leukaemia syndrome, an often aggressive leukaemia/ lymphoma of mature T-cell lymphocytes, which clusters in
southern Japan and in the Caribbean basin or in migrants from these areas. ATL occurs at a rate of 2-4 per 100,000
per year in viral endemic areas with a lifetime risk of approx- imately 3-5% in seropositives. HTLV associated
myelopathy/tropical spastic paraparesis (HAM/TSP), a
chronic myelopathy has also been associated with HTLV-I.
In addition to parenteral transmission by blood transfusion
and needle sharing among drug abusers, HTLV-I is also
transmitted by sexual intercourse and from mother to child
(transplacental (rare) and via breast milk). Sexual transmis-
sion is more efficient from male to female but female to male
transmission involving the coincidence of ulcerative genital lesions and male to male transmission have been documented. In viral endemic areas there is a strong age dependent rise in seroprevalence with a female predominance due to the more efficient transmission of the virus from males
to females. The female excess of TSP cases may reflect the
shorter latency between exposure and disease compared to ATL where early life exposure may determine subsequent risk for leukaemia of longer latency.946 BACR/ACP/LRF JOINT WINTER MEETING
Abstracts of members' proffered
papers
Cytogenetic and molecular identification of t(14;18) in fol-
licular and extranodal lymphoma
H. Clark, K. Higginson, D.B. Jones, P. Jacobs & D.H.
Wright
University Pathology, General Hospital, Southampton S09
4XY and Regional Cytogenetics Unit, General Infirmary,
Salisbury, UK.
The t(14;18) translocation is considered characteristic of fol-
licular and some cases of diffuse B-cell lymphoma and is
thought significant in the pathogenesis of follicle centre cell
tumours. We have augmented the cytogenetic analysis of
B-cell tumours with molecular probes recognising both major
and minor translocation breakpoints. Southern blotting using
molecular probes has enabled the retrospective analysis of
frozen biopsies from the routine files. In particular, we have
compared extranodal lymphomas, thought to arise from
mucosa-associated tissue, with tumours clearly of follicular
type. A variety of histological types of lymphoma have been
examined. Of these, 30% of the follicular and 20% of the
diffuse B-cell lymphomas exhibited t(14;18), demonstrated by
both cytogenetic and/or Southern blot analysis. None of the
extranodal lymphomas examined exhibited t(14;18). A
preliminary study of DNA extracted from routine paraffin
embedded biopsies confirms the observations made on fresh
and frozen biopsy tissue. These data are significant in terms
of our understanding of the pathogenesis of lymphoma of
mucosa-associated lymphoid tissue and also point to the
value of human chromosomal breakpoint probes in ret-
rospective studies of human lymphoma series.
Estimation of number of cells bearing t(14;18) in pathological
samples from patients with follicular lymphoma using an
adapted PCR technique
C.G.A. Price, F.E. Cotter, A.Z.S. Rohatiner, T.A. Lister &
B.D. Young
ICRF Department of Medical Oncology, St Bartholomew's
Hospital, London ECI, UK.
A 4-stage adaptation to standard PCR incorporating the use
of 'nested' internal primers (Mullis & Faloona, 1987,
Methods Enzymol., 155, 335) and a modification of the
primer 'booster' technique (Ruano, Fenton & Kidd, 1989,
Nucleic Acid Res., 17, 5407) has been developed to give a
high probability of achieving positive amplification from a
single target molecule, even where this is present in 1 fg of
total DNA. This 4-stage PCR can be applied to serial dilu-
tions of DNA from pathological samples, and the dilution
required to abolish positive results used to estimate the star-
ting frequency of target molecules. Differences of less than I
log between samples can readily be detected if several
amplification reactions are run in parallel. This technique has
been applied to material obtained from patients with lym-
phoma associated with t(14;18). 'Outer' primers for the initial
stages of the reaction were complementary to JH heavy chain
joining region J6 and a sequence flanking the mbr or bcl 2.
'Nested' primers were complementary to JH consensus region
and an internal mbr sequence. The technique was verified by
obtaining consistent estimates of target molecule frequency in
a given sample across a range of test dilutions, even where
the observed and expected frequency was <1 per 20
amplification reactions. Clinical correlations with
measurements so obtained from sequential samples can be
made. For example, t(14;18) cells were shown to make up a
steady 1% of the mononuclear fraction of peripheral blood
in samples taken from a patient with stage IV (marrow)
disease for 1 year during which she was observed off treat-
ment with no change in other measurable parameters of
disease. A second patient in whom an estimated 0.1%
t(14;18) cells were present in autologous marrow returned
after ablative chemoradiotherapy has reappearance of the
translocation in peripheral blood (<1 copy per 105 mono-
nuclear cells) at 1 year. The significance of this will be
determined from further follow-up.
Direct sequence analysis of reciprocal t(14;18) junctions in
follicular lymphoma
F.E. Cotter, C.G.A. Price & B.D. Young
ICRF Department of Medical Oncology, St Bartholomew's
Hospital, London EC], UK.
The t(14;18) translocation is a consistent characteristic of
follicular lymphoma and has been shown to involve the
juxtaposition of the bcl-2 gene into the IGH locus. It has
been proposed that this event can occur as a mistake in
V-D-J joining or, alternatively, through a strand scission and
repair mechanism. In order to address this question, a series
of bcl-2/Ig junctions on der (14) chromosomes was examined
by PCR amplification and direct sequence analysis. In most
patients, the bcl-2 gene was fused to a JH sequence with a
short intervening region of unidentifiable sequence, usually
considered to be N-region. In one patient, however, a bcl-2/
Ig junction was found which juxtaposed bcl-2 next to a DH
sequence which itself had been arranged to lie next to a 6
sequence. This DH gene was identical to one previously
shown to lie just 5' of a t(14;18) breakpoint. This unusual
configuration supports the idea that at least some the 'N'
regions found at breakpoints might represent parts of
previously unknown DH regions. A PCR strategy was also
devised for a similar analysis of the der (18) junctions. One
primer, corresponding to part of the heptamer-nonamer
recombination signal region of DH genes was used for the
chromosome 14 side of the junction. It was thus possible to
sequence directly both reciprocal junctions in a particular
tumour, showing that the bcl-2 sequence was conserved dur-
ing translocation, with none of the deletions or duplications
noted by others. Taken together these data suggest that the
t(14;18) translocation can disrupt both germline JH and rear-
ranged VH-DH and DH-JH regions and need not result in loss
or duplication of bcl-2 sequence.
Immunocytochemical study of the bcl-2 gene product
F. Pezzella, A. Tse, J.C. Cordell, K.C. Gatter & D.Y. Mason
Nuffield Department of Pathology, John Radcliffe Hospital,
Headington, Oxford OX2 9DU; Sir William Dunn School of
Pathology, South Parks Road, Oxford OX], UK.
The 14;18 translocation, associated with follicular lymphoma,
brings a portion of the immunologlobulin heavy chain gene
on chromosome 14 into juxtaposition with the bcl-2 gene on
chromosome 18. Cells bearing the 14;18 translocation pro-
duce mRNA encoding bcl-2, and a study by Ngan et al.
(1989), using a polyclonal antiserum against recombinant
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restricted to follicular lymphoma and to a minority of diffuse
lymphomas (in which the 14;18 translocation occasionlly
occurs). No staining of normal cells or of other lymphomas
was observed. We have used polyclonal and monoclonal
reagents against a peptide sequence from the bcl-2 protein in
an immunocytochemical study of normal and neoplastic tis-
sue. Mature T cells (in lymph node and thymic medulla) and
small B cells (in mantle zones) are labelled but proliferating
B and T cells (in germinal centres and thymic cortex respec-
tively) show little or no staining. Many cases of follicular
lymphoma are strongly stained for bcl-2 protein, but equally
strong labelling was also observed in other types of lym-
phoma, including hairy cell leukaemia, immunocytoma and T
cell neoplasms. In conclusion, we have confirmed the findings
of Ngan et al. that bcl-2 immunostaining distinguishes
between normal and neoplastic germinal centres. However,
the extensive staining of normal lymphoid cells and of many
non-follicular neoplasms suggests that bcl-2 protein may be
produced in the absence of the 14;18 translocation and is not
therefore a specific marker for this cytogenetic abnormality.
A rapid PCR method for distinguishing clonal from polyclonal
B-cell populations in surgical biopsies
rearranged or, in the case of the 6 gene, deleted in the
majority of both T and B lineage ALLs. Both genes are
characterised by a relatively limited germ-line encoded reper- toire and by extensive V-(D)-Jjunctional diversity; due to the
deletion and/or addition of nucleotides by the enzyme TdT.
Such localisation of diversity renders study of these junc- tional sequences fundamental to our further understanding of
TCR arrangements. We have PCR amplified and directly
sequenced presentation DNA using V and J segment specific primers from 23 cases of T-ALL (42 TCR y alleles, 13 TCR
V61-J61 alleles) and eight cases of B lineage ALL (10 TCR -y
alleles). This demonstrated extensive junctional diversity (especially in TCR6 rearrangements) and has allowed us to
determine the frequency with which these rearrangements are
potentially functional (TCR7 37%, TCR6 54%). We have
correlated gene rearrangement with surface phenotype and
show that, unlike mature T cells, a high percentage of CD3 + T ALLs express TCR'y6 (5/10 cases, including CD4+ and/or CD8 + cases). Furthermore, the extensive junctional diversity provides ideal clone specific markers. We have used anti-
TCRy and 6 junctional oligonucleotide probes specifically to
detect PCR amplified B and T-cells at dilutions of up to 10'
in germline DNA and to differentiate clonal from normal
polyclonal T cell DNA.
K.P. McCarthy, J.P. Sloan & L.M. Wiedemann
Leukaemia Research Fund Centre at Institute for Cancer
Research, London SW3 6JB, UK, and Department of Histo-
pathology, Royal Marsden Hospital, Sutton SM2 5PT, UK.
It can be difficult to distinguish a neoplastic, monoclonal
B-cell proliferation from a polyclonal lymphoid proliferation
on the basis of morphology and immunophenotype. Early in
the development of the B-cell, the DNA of the immuno-
globulin (Ig) heavy chain locus undergoes a series of
rearrangements which result in a unique combination of
variable (VH), diversity (DH), and joining (JH) segments
separated by TdT inserted N-regions. It is now a relatively
common practice to isolate and analyse DNA by restriction
enzyme digests and hybridisation in order to determine
whether clonal rearrangement of the immunoglobulin heavy
chain gene is present, but this requires a relatively large
specimen. We have employed the polymerase chain reaction
(PCR) in order to detect the presence of monoclonal VH-DH-
JH rearrangements using primers predicted from the con-
served sequences of the surrounding VH and JH segments.
This procedure requires I jig or less of DNA and is more
rapid than the conventional Southern blot protocols. We
have found that in DNA from a polyclonal lymphoid
population, the amplified PCR fragments result in a 'smear'
when analysed by polyacrylamide gel electrophoresis. This is
probably due to the variation in length of the N-regions in
addition to the variability in length of the DH segments. In
contrast, in 7/11 B-cell lymphomas analysed, a discrete band
is observed following PCR (Ig-PCR positive), as all tumour
cells, being progeny of a single cell and having undergone a
unique Ig heavy chain rearrangement, possess N and DH
combination of the same sequence and length. Two out of
four of the Ig-PCR negative samples and one out of seven of
the Ig-PCR positive samples were rearranged in the BCL2
major breakpoint region as analysed by PCR.
Analysis of TCR 76 gene rearrangements in ALL using PCR
amplification of V-(D)-J junctions and direct nucleotide
sequencing
E. Macintyre, L. d'Auriol, F. Galibert & F. Sigaux
Inserm 301 and CNRS UPR 48, HOpital St Louis, Paris,
France.
Although the 76 T cell receptor (TCR) is only expressed on a
small minority of mature T lymphocytes, these genes are
Expression of the P190 ber-abl protein in an EBV immor-
talised lymphoblastoid cell line
B.D. Young, B. Gibbons, T. Chaplin & S. Dhut
ICRF Department of Medical Oncology, St Bartholomew's
Hospital, London ECI, UK.
Each Philadelphia (Ph') translocation event results in the
expression of one member of a family of chimaeric bcr-abl proteins. A sub-group of Ph' chromosome positive ALL
patients have been identified which expresses the P190 bcr-abl protein which, so far, has not been identified in any CML
patients. The relationship of this sub-group of lymphoid leukaemias to those which express the P210 bcr-abl protein remains unclear. To understand this relationship further cells
from an ALL patient expressing the P190 bcr-abl protein
were subjected to EBV immortalisation and, after repeated cloning and karyotype analysis, a cell line was derived which
carried the Ph' translocation. Continued expression of the P190 bcr-abl was demonstrated using a monoclonal antibody which recognises the N terminal region of this protein. Com-
parison of the karyotype of this cell (46 XX t(9;22) with that of the original leukaemic cells (55, XXX, + 2, + 4, + 8, + 10, + 14, + 21, + 21,t(9;22), + Ph') revealed that it must be derived from the earliest stage of karyotype evolution.
Differences in the pattern of JH hybridisation indicated that the cell line represents a different clone from the leukaemia with respect to Ig rearrangement. This finding is consistent with the idea that the Philadelphia translocation, which pro- duces the P190 bcr-abl protein, precedes immunoglobulin
gene arrangement.
A new human B-cel non-Hodgkin's cell line (K422) exhibiting both t(14;18) and t(4;11) chromosomal translocations
M.J.S. Dyer, P. Fischer, E. Nacheva, W. Labastide & A.
Karpas
University of Cambridge, Department of Haematology, Hills
Road, Cambridge CB2 2QH, UK.
The association between cytogenetic abnormalities and the phenotype of haematologic malignancies is well established. A paradigm is the occurrence of the t(l4;18) in B cell fol- licular lymphoma. Similarly the t(4;I 1) has been found948 BACR/ACP/LRF JOINT WINTER MEETING
predominantly in B-cell leukaemias of infancy. We describe a
unique B-cell non-Hodgkin's lymphoma cell line (K422)
bearing both t(14;18) and t(4;11) chromosomal translocations
as well as several other chromosomal abnormalities, derived
from the pleural effusion of a patient with chemotherapy-
resistant non-Hodgkin's lymphoma. This cell line has the
same karyotypic features as malignant cells from the patient.
The major cell clone is characterised chromosomally by
46,XX t(2;10) (p23; q22.1), t(4;11) (q21.3; q23.1), t(14;18)
(q32.1; q22.2), t (4;16) (q21.3; p13.1). Both phenotypically
and genotypically the cell line has features of a mature B cell
neoplasm with no evidence for commitment to other lineages.
Rearrangements of the C-ETS-1 oncogene and N-CAM-1
and CD3 genes which map to l1q23 were not detected by
conventional Southern analysis. BCL-2 was rearranged
within the major breakpoint cluster. The K422 cell line has a
unique karyotype; this is the first occasion that the t(4;11)
translocation has been described in a t(14;18) lymphoma. The
cell line will be of value in determining the molecular nature
of the t (4;11) translocation.
Myc oncogene rearrangement in the absence of chromosomal
change in blast crisis of B-cell lymphoma
M.J.S. Dyer, P. Fischer & R. Marcus
University of Cambridge, Department of Haematology, Hills
Road, Cambridge CB2 2QH, UK.
We describe a case of lymphoblastic lymphoma in leukaemic
phase where the t(14;18) was the sole cytogenetic change but
which had clear molecular evidence of myc rearrangement. A
75-year-old lady presented with abdominal pain, weight loss,
hepatoplenomegaly but no lymphadenopathy, Hb 6.9,
platelets 25, WCC 19.6 (100% lymphoblasts). Immuno-
phenotyping was consistent with a mature B-cell neoplasma
apart from a lack of detectable immunoglobulin heavy chain.
Kappa light chain was detectable in the cytoplasm only.
Cytogenetic analysis showed t(14;18) as the only structural
change. Genotypic analysis revealed rearrangement not only
of BCL-2 but also of the myc oncogene. Characterisation of
the rearranged fragment is in progress. Lack of immuno-
globulin heavy chain and the preliminary mapping of the
rearranged myc fragment lead us to suspect that the myc
rearrangement may represent a cytogenetically 'cryptic'
t(8;14). This case appears to be analogous to cytogenetically
normal cases of CML which nevertheless have molecular
evidence for bcr-abl rearrangement.
The application of regionalised variable theory to the study of
childhood cancer clusters
M. Oliver, K.R. Muir, S.E. Parkers & J.R. Mann
School of Geography, University of Birmingham B15 2TT,
Department of Oncology, Birmingham Children's Hospital,
Birmingham B16 8ET, UK.
Regionalised variable theory (RVT) was developed to analyse
spatially distributed properties that vary in a random,
unpredictable manner. Early applications of its methods were
in the mining industry to estimate the amount of metal/
mineral in ore deposit. The central tool of RVT is the
variogram which defines the pattern and spatial scale of the
variation. Once the variogram has been modelled we can use
the model parameters for estimation by kriging. Kriging is an
optimal estimation procedure that uses the form of the
spatial variation contained in the variogram to provide the
best possible estimates with known confidence. The spatial
variation can then be mapped isarithmically.
We are investigating the possibility of applying kriging to
the incidence of childhood cancer. The problems -we face
relate to the low rates, the statistical distribution and the lack
of continuity in the variation. This last problem has been
faced by workers in diamond mining, yet they have found the
methods of value for predicting high concentrations. We can
use the more advanced technique of disjunctive kriging to
transform the distribution using hermite phynomials. If the
spatial variation of childhood cancer is second order sta-
tionary, the technique may be used further to set a critical
threshold of incidence and to determine the probability of
exceeding this value.
This technique is being applied to the data of the West
Midlands Regional Children's Tumour Registry. This
specialised registry contains data on all cases of childhood
cancer in the West Midlands Health Authority Region. Cases
diagnosed between 1975 an 1984 have been mapped and their
distribution assessed using Poisson probability mapping. The
results of this form of analysis are being compared with the
assessment of clustering through the methods of RVT. A
comparison of the results by both methods is given.
Adult T-cell leukaemia/lymphoma (ATLL) in Brazil. Evidence
for a new endemic area for HTLV-1
E. Matutes, M.P. de Olivera, T.S. Shulz, M.J. Andrada-
Serpa, M.L. Calabro, R. Weiss & D. Catovsky
Institute of Cancer Research, London, and Instituto Nacional
de Cancer, Rio de Janeiro, Brazil.
We describe a series of 12 patients with ATLL diagnosed
over a period of 2 years in Rio de Janeiro. The disease had
typical clinical features and malignant cells with a CD4 +,
CD25 +, CD8- and CD7- membrane phenotype. This series
includes an 18-month-old black infant whose mother and
grandmother were HTLV-1 seropositive. Seven of the 12
patients were black or mulatto race and five were whites, four of Portuguese descent. Serological assays for HTLV-1
were positive in seven out of eight cases tested and these
results were confirmed by Southern blotting of patients DNA
using a full length HTLV-1 probe. The disease in Brazil is
indistinguishible from ATLL in the other endemic areas,
southwestern Japan and the Caribbean basin. There is
independent seroepidemiological evidence for HTLV-1 infec-
tion in Brazil (Cortes et al., NEJM, 320, 1989, 953; Andrada-
Serpa, Int. J. Cancer, 1990, in the press). This report
confirms the presence of the T-cell malignancy caused by
HTLV-1 in the Brazilian population. Studies on the mode of
transmission of the retrovirus in Brazil and other South
American countries are necessary.
Identification of immunologically reactive epitopes on the GAG
proteins of HTLV-1
S. Gledhill, S. Crae, R.S. Tedder, M. Robert-Guroff, D.E.
Onions & R. Jarrett
LRF Virus Centre, Glasgow University Veterinary School,
Glasgow G61 IQH; Dept ofMedical Microbiology, University
College and Middlesex School of Medicine, London WIP
7PN; Laboratory of Tumour Cell Biology, NCI, NIH,
Bethesda, MD 20892, USA.
Using Western blot assays, cross-reacting antibodies to
HTLV-1 gag proteins have been detected in sera from
patients with cutaneous T-cell lymphoma (Ranki & Krohn,
1987, Viruses in Human Cancer, p.47) and from healthy
blood donors (Schupbach et al., 1983, J. Exp. Med., 157,
907). In addition some monoclonal antibodies raised against
HTLV-1 p19 cross-react with normal and malignant tissues
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In order to identify the immunologically reactive epitopes
on the gag proteins of HTLV-1 we have synthesised overlap-
ping peptides covering p19 and p24. We have identified an
epitope near the carboxyl terminus of p19 recognised by a
monoclonal antibody reactive with p19 but which also cross-
reacts with other tissues (Robert-Guroff et al., 1981, J. Exp.
Med., 154, 1957). Sera from HTLV-1 seropositive patients
show reactivity with two regions near the carboxyl terminus
of p19.
We are investigating the epitopes recognised by HTLV-2
positive sera and those recognised by sera classified as
HTLV-1 negative according to accepted criteria, which con-
tain antibodies reactive with viral gag proteins. The results of
these investigations should assist in determining the
significance of cross-reactive antibodies in the sera of non
HTLV-1-infected persons.
Activation of HTLV-1 and HSV-1 promoter constructs by
HHV-6
M. Campbell, S. McCorkindale & R. Everett
Leukaemia Research Fund Virus Centre, Veterinary School,
Glasgow G61 IQH; MRC Institute of Virology, Church
Street, Glasgow GIl 5JR, UK.
Human herpes virus type 6 (HHV-6) is able to replicate in T
cells and therefore may act as co-factor in the activation of
Human T Cell Leukaemia Virus (HTLV-1). In order to study
the interaction between the two viruses J Jhan cells were
transfected with HTLV-1 LTR CAT constructs and infected
with HHV-6. A 200-fold increase in CAT expression was
observed compared to non infected controls. Time course
studies showed activation of the HTLV-1 CAT construct to
be due to HHV-6 proteins produced early in infection.
Activation by HHV-6 and HTLV-1 tax is synergistic. In
addition, an HTLV-1 CAT construct in which the 21bp
repeat tax responsive sequences were deleted was still
strongly induced by HHV-6 although basal levels of expres-
sion were greatly reduced showing HHV-6 and HTLV-1 tax
to operate by different mechanisms. In order to determine if
any basal regulatory elements are required for activation by
HHV-6 a series of HSV-1 gD promoter deletion mutants are
being studied.
The seroepidemiology of HHV-6 in a case controlled study of
leukaemia and lymphoma
D. Clark, F. Alexander, P. McKinney, R. Jarrett, R. Cart-
wright & D. Onions
LRF Virus Centre, Dept Veterinary Pathology, University of
Glasgow, Glasgow G61 IQH; LRF Clinical Epidemiology Cen-
tre, University of Leeds, Leeds LS2 9NG, UK.
The association of human herpesvirus-6 (HHV-6)
seropositivity and antibody titre with haematological malig-
nancies was examined utilising 940 sera from a case cont-
rolled epidemiological survey.
In an indirect immunofluorescence assay 55% of the cont-
rol sera were positive for HHV-6 antibody at a titre > 1:40
and there was a significant increase in geometric mean titre
(GMT) in females. Analysis of individual disease subtypes
showed there was a strong association between HHV-6
seropositivity and titre in acute myeloid leukaemia, Hodg-
kin's disease (HD) and low-grade non-Hodgkin's lymphoma;
the GMT ratios of cases to controls being 3.97, 2.94 and 5.2
respectively (95% CI).
These results may reflect altered patterns of HHV-6 rep-
lication or reactivation in these conditions. In HD, however,
there was evidence for increased titres and seropositivity in
young cases that lacked siblings in the family. It is possible
that late infection by HHV-6 is occurring in these cases and
the immune response to HHV-6 may play a role in the
pathogenesis of HD.
Virus involvement in Hodgkin's disease
S. Gledhill, A. Gallagher, E. Klee, D. Jones, A.S. Krajewski,
D.E. Onions & R.F. Jarrett
LRF Virus Centre, Veterinary School, Glasgow University,
Glasgow; Southampton General Hospital, Southampton S09
4XY; Department of Pathology, University of Edinburgh
Medical School, Edinburgh, UK.
Epidemiological studies have suggested that Hodgkin's
Disease (HD) might have a viral aetiology. Herpes viruses
have been implicated by serological studies showing elevated
serum antibodies to EBV (Evans & Gutensohn, 1984, Int. J.
Cancer, 34, 149) and HHV-6 (Clark et al., submitted) in HD
cases. In addition, one report has described the detection of
HTLV-1 by PCR in a case of HD (Duggan et al., 1988,
Blood, 71, 1027).
In a series of 37 cases of HD which were analysed for the
presence of immunoglobulin heavy chain (IgH) and T-cell
receptor (TCR) gene rearrangements, we used Southern blot
analysis to look for the presence of EBV and HHV-6 DNA.
PCR was used to look for the presence of HTLV-l DNA
sequences.
Approximately 1/4 of the cases showed IgH gene re-
arrangements, TCR genes were germline. We did not detect
HHV-6 DNA in any of the samples. Of 18 samples analysed
for the presence of EBV DNA 6 were positive. Detection of
EBV did not correlate with the detection of IgH gene re-
arrangements. HTLV-1 sequences were not amplified in any
of 20 samples analysed using PCR.
These results suggest that EBV may play a role in the
pathogenesis of some cases of HD.
P-glycoprotein (PGp) expression and glutathione (GSH) con-
tent in human leukaemia cells determined by flow-cytometry
(FCM)
M.R. Muller, P.R. Twentyman, E. Lambert, H. Cox, J.V.
Watson, T.P. Baglin & J.H.K. Rees
MRC Clinical Oncology and Radiotherapeutics Unit and
University Department of Haematology, Cambridge, UK.
PGp expression and GSH content can be determinants of
cytotoxic drug resistance in cancer cells. We have established
optimal conditions for measuring these parameters in human
leukaemia cells by FCM. To determine PGp expression
isolated cells were stained with the monoclonal antibody
MRK16 and FITC-labelled rabbit-antimouse serum and
fixed in paraformaldehyde. Cells were also stained with pro-
pidium iodide and a DNA-histogram simultanously recorded.
To date, 20 patients with haematological malignancies have
been investigated. Three patients with clinically resistant
AML, CLL and CML in blast crisis had more than 40%
positive cells. Four non-responsive and 14 untreated patients
were negative for PGp. There was no direct relationship
between the in vitro responsiveness to adriamycin determined
by the MTT assay and PGp content in patients studied to
date. We have previously observed a good correlation
between the cellular GSH content of H69 human lung cancer
cells after BSO-depletion as determined by FCM using the
probe monochlorobimane and by spectrophotometry (Tietze-
assay). This correlation was also found in determination of
GSH-content in isolated lymphocytes from 14 patients with
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patients with clinically resistant CLL (88 ng per i0' cells, 736
fluorescence units (FU)) compared to six untreated CLL
patients (37.7 ng per 105 cells, 443 FU) and eight healthy
individuals (46.5 ng per 105 cells, 482 FU). Interestingly,
these non-responsive patients with elevated cellular GSH
content were negative for PGp-staining. Studies are under-
way to investigate the role and relationship of PGp and GSH
to cytotoxic drug sensitivity determined in the MTT-assay
and to clinical responsiveness.
Multidrug resistance in chronic lymphatic leukaemia
P. Cumber, R.A. Padua, J. Holmes, G. Carter & A. Jacobs
LRF Preleukaemia Unit, University of Wales College of
Medicine, Heath Park, Cardiff, UK.
Chronic lymphocytic leukaemia (CLL) is generally a disease
of slow progression and is resistant to cytotoxic treatment.
Drug resistance mechanisms may therefore be potentially
relevant in CLL. The multidrug resistance gene mdr I
encodes a transmembranous p-glycoprotein which effectively
acts as an efflux pump leading to a decreased intracellular
concentration of cytotoxic drugs. We have studied 34
patients with CLL (seven untreated, 27 treated); DNA was
screened for gene amplification, RNA for increased expres-
sion of mdr 1 and p-glycoprotein for exptession using FACS
analysis and a monoclonal antibody to the external epitope
(MRK-16). Normal control lymphocytes from 10 healthy
volunteers were prepared and levels of RNA expression and
protein in these samples were found to be low relative to
vinblastine sensitive and resistant cell lines. Eighteen patients
(four untreated, 14 treated) were observed to have mdr 1
RNA expression levels above the normal range. No DNA
amplification was found in any samples investigated. The
p-glycoprotein levels were elevated in five (one untreated and
four treated) of these CLL patients. The discrepancy between
the high incidence of increased RNA levels and apparently
low protein expression in CLLs may be explained by mask-
ing of p-glycoprotein on the cell surface membrane.
The identification of drug resistance and cross-resistance pat-
terns in acute myeloid leukaemia (AML)
J.M. Sargent, C.G Taylor, A.W. Elgie & J.K. Wilson
Dept ofHaematology, Pembury Hospital, Pembury, Kent TN2
4QJ, UK.
The identification of drug resistance in individual patients
before treatment would be a therapeutic advance in the
management of AML. The advantages of short-term in vitro
drug sensitivity assays are now being recognised. We have
validated the use of the rapid and simple MTT assays for
chemosensitivity testing of blast cells from AML (Sargent &
Taylor, 1989, Br. J. Cancer, 60, 206). There is a good
reproducible variation in drug effect between patients. The
assay results correlated with the clinical response in 21 of 23
cases. In 16 patients with de novo disease tested against up to
seven drugs, one showed resistance to all agents tested, four
were resistant to doxorubicin, one to mitoxantrone and eight
to cytosine arabinoside. Of the four resistant to doxorubicin,
three were sensitive to mitoxantrone. Four patients were
tested against doxorubicin, mitoxantrone and daunorubicin.
The one sample resistant to doxorubicin in this group was
also resistant to mitoxantrone but sensitive to daunorubicin.
This assay can not only predict de novo resistances but,
because of its simplicity and efficiency, it can be used
throughout the course of the disease to detect changes in
sensitivity. Sequential analyses in two patients over several
months demonstrated increasing resistance to doxorubicin.
The test is a suitable method to study the in vitro effect of
potential resistance modifiers, for example the calcium
antagonist verapamil significantly increased sensitivity to
doxorubicin. Few cells are required for the MTT assay so, in
addition to dose response curves for single agents it was
possible in 11 patients, to construct a model to mimic the
standard combination drug regimes. No evidence of syner-
gism was found. To conclude, the reliability, speed and
simplicity of the MTT assay facilitates the study of drug
resistance and resistance modifiers in AML.
Alternative anthracycfines and resistance modifiers in human
leukaemias. An in vitro study using the MTT assay
P.R. Twentyman, M. Muller, E. Lambert & J.H.K. Rees
MRC Clinical Oncology and Radiotherapeutics Unit and
University Department of Haematology, Hills Road, Cam-
bridge CB2 2QH, UK.
In studies using multidrug resistant (MDR) cell lines, we
have developed two strategies for overcoming resistance. The
first involves the identification of alternative drugs which
retain activity in MDR cells and the second uses resistance
modifiers (RMs) to restore sensitivity. These approaches have
now been tested in human leukaemias using peripheral blood
cells and in vitro chemosensitivity testing using a 4 day MTT
assay (Twentyman et al., Br. J. Haematol., 1989,.71, 19). We
have determined sensitivity to adriamycin (ADM), vincristine
(VCR) and melphalan (MEL), the alternative anthracyclines
aclacinomycin A (ACL) and the Japanese morpholinyl com-
pound MX2, together with resistance modifiers verapamil
(VRP, 2 tM) and cyclosporin A (CYA, 0.8 tLM). To date 10
samples of normal lymphocytes (NL), 26 CLL, 3CML and
2AML have been studied. Sensitisation ratios (i.e. ratio of
cytotoxic drug ID50s in absence/presence of RM) obtained
are shown below in the table.
ADM VCR MEL ACL MX2
VRP CYA VRP CYA VRP CYA VRP CYA VRP CYA
NL 1.1 - 1.1 - - - - - - -
CLL 1.4 1.2 2.6 3.1 1.0 - 1.0 1.9 1.1 1.1
AML + CML 1.5 1.7 1.6 1.9 0.9 - 1.0 0.9 1.1 0.9
The relative efficacies of ACL and MX2 (compared to
ADM) were higher for AML + CML samples than for CLL
or NL. These data indicate that RMs po-tentiate the potency
of 'classic' MDR-type drugs (ADM,VCR) in leukaemic cells
but not in NL. No such potentiation is seen for MEL or the
'low-resistance' drugs ACL and MX2. Such studies may
facilitate the optimisation ofchemotherapy for leukaemias on
an individual patient basis.
Use of the MTT assay to assess drug resistance patterns in
acute myeloid leukaemia (AML)
J.K. Phillips
Liverpool University Department o] Haematology, Royal
Liverpool Hospital, Prescot Street, Liverpool L69 3BX, UK.
Cytotoxics affected by multidrug resistance (MDR) in vitro
are major components of AML chemotherapy, but the
relevance of this phenomenon to clinical resistance is unclear.
Using the MTT assay this study aims to establish in AML:
(1) the range of dose-response curves to four MDR
(mitozantrone, adriamycin, VP16, vincristine) and two non-
MDR cytotoxics (cytosine, thioguanine); (2) to what extent in
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frequency of the MDR phenotype. Blasts purified from peri-
pheral blood/bone marrow in 23 patients showed wide ranges
of ID50s (cytotoxic concentrations giving 50% reduction in
optical density (OD) after 72 h cytotoxic exposure for all six
drugs. No significant difference was seen between relapsed
(n = 7) and untreated (n = 16) groups. Percentage reduction
in OD at cytotoxic concentrations corresponding to approx-
imately 1/10 peak achievable plasma levels (>70% = sen-
sitive, <70% = resistant) Bird et al., Cancer, 1988, 61, 1104)
correctly predicted clinical response in only four of 12 sam-
ples for which relevant in vivo and in vitro data are available.
In 12 samples all six drugs were tested in the presence and
absence of 6.6 tM verapamil (VER). Four of these (two
relapsed, two untreated) showed a clear increase in sensitivity
to MDR drugs in the presence of VER but in none were all
four drugs affected. In vitro sensitivity to non-MDR drugs
was not increased by VER.
In vitro sensitivity to component drugs measured by MTT
assay predicts poorly for clinical response to combination
chemotherapy. VER modification of MDR drug sensitivity in
vitro is seen in both untreated and relapsed AML.